vimarsana.com

Page 24 - உயிரி தொழில்நுட்பவியல் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TÜBİTAK Başkanı Prof Dr Mandal, yerli aşı ve ilaç çalışmalarıyla ilgili konuştu: (2)

TÜBİTAK Başkanı Prof Dr Mandal, yerli aşı ve ilaç çalışmalarıyla ilgili konuştu: (2)
haberler.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from haberler.com Daily Mail and Mail on Sunday newspapers.

Indian Institute of Technology-Kanpur Collaborates With I2Cure For Future-ready Research On Molecular Iodine Based Products

Share New Delhi: The Indian Institute of Technology-Kanpur (IIT-K) has collaborated with I2Cure (P) Ltd, a ‘Make in India for the world’ Biotech company for all future research on Molecular iodine-based products that would be undertaken by the Biological Sciences & Bioengineering wing of IIT-K (https://www.iitk.ac.in/bsbe/). I2Cure is the first Biotechnology Company in the world to produce Molecular Iodine-based i2cure BioShield’, which is a broad-spectrum antimicrobial with proven efficacy of 99.999% against the SARS2 Covid virus.   Under the terms of the agreement, I2Cure future products would be incubated at IIT-Kanpur. The relationship would be of the equity partners, and validations of Dr. Jack Kessler’s global research would be done for Indian conditions at IIT-K. IIT-K would also work with I2Cure to develop new ‘Made in India’ products for global markets, especially in tackling long-term problems in the space of Human Preventive Health, Veterinary science (FMD,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.